Rhumbline Advisers Has $112.32 Million Position in Becton, Dickinson and Company (NYSE:BDX)

Rhumbline Advisers cut its holdings in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 1.4% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 495,076 shares of the medical instruments supplier's stock after selling 7,159 shares during the quarter. Rhumbline Advisers owned approximately 0.17% of Becton, Dickinson and Company worth $112,318,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in BDX. Good Life Advisors LLC boosted its holdings in shares of Becton, Dickinson and Company by 20.9% during the third quarter. Good Life Advisors LLC now owns 1,145 shares of the medical instruments supplier's stock valued at $276,000 after acquiring an additional 198 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd lifted its holdings in shares of Becton, Dickinson and Company by 2.0% in the third quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 33,045 shares of the medical instruments supplier's stock valued at $7,967,000 after buying an additional 633 shares during the period. Stonegate Investment Group LLC lifted its holdings in shares of Becton, Dickinson and Company by 5.0% in the third quarter. Stonegate Investment Group LLC now owns 5,536 shares of the medical instruments supplier's stock valued at $1,335,000 after buying an additional 264 shares during the period. Aspiriant LLC raised its position in Becton, Dickinson and Company by 8.4% in the third quarter. Aspiriant LLC now owns 1,171 shares of the medical instruments supplier's stock worth $282,000 after acquiring an additional 91 shares in the last quarter. Finally, Stratos Wealth Advisors LLC raised its position in Becton, Dickinson and Company by 9.8% in the third quarter. Stratos Wealth Advisors LLC now owns 3,274 shares of the medical instruments supplier's stock worth $790,000 after acquiring an additional 291 shares in the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 700 shares of the stock in a transaction dated Wednesday, February 12th. The stock was sold at an average price of $227.99, for a total value of $159,593.00. Following the completion of the sale, the director now directly owns 36,033 shares in the company, valued at $8,215,163.67. This represents a 1.91 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Roland Goette sold 4,483 shares of Becton, Dickinson and Company stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $221.01, for a total transaction of $990,787.83. Following the completion of the transaction, the executive vice president now directly owns 24,345 shares in the company, valued at approximately $5,380,488.45. The trade was a 15.55 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 10,544 shares of company stock worth $2,370,309 in the last quarter. 0.36% of the stock is owned by company insiders.

Becton, Dickinson and Company Price Performance

Shares of BDX traded up $2.43 on Wednesday, hitting $227.56. The company's stock had a trading volume of 1,068,545 shares, compared to its average volume of 2,113,158. The company has a market capitalization of $65.34 billion, a PE ratio of 37.80, a PEG ratio of 1.61 and a beta of 0.40. Becton, Dickinson and Company has a fifty-two week low of $218.75 and a fifty-two week high of $251.99. The company has a 50 day moving average price of $232.72 and a 200 day moving average price of $233.42. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.13 and a quick ratio of 0.63.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings data on Wednesday, February 5th. The medical instruments supplier reported $3.43 EPS for the quarter, topping analysts' consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. On average, research analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company announced that its board has approved a stock repurchase plan on Tuesday, January 28th that authorizes the company to repurchase 10,000,000 shares. This repurchase authorization authorizes the medical instruments supplier to reacquire shares of its stock through open market purchases. Shares repurchase plans are generally an indication that the company's management believes its stock is undervalued.

Becton, Dickinson and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, March 31st. Investors of record on Monday, March 10th will be issued a $1.04 dividend. This represents a $4.16 annualized dividend and a yield of 1.83%. The ex-dividend date is Monday, March 10th. Becton, Dickinson and Company's dividend payout ratio is 69.10%.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on BDX shares. Barclays raised their target price on shares of Becton, Dickinson and Company from $278.00 to $279.00 and gave the stock an "overweight" rating in a report on Friday, February 14th. StockNews.com upgraded Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a report on Wednesday, February 12th. Finally, Piper Sandler boosted their target price on Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an "overweight" rating in a research report on Tuesday, January 28th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $278.29.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.